{
    "name": "piflufolastat F 18",
    "comment": "Rx",
    "other_names": [
        "Pylarify"
    ],
    "classes": [
        "Diagnostic Imaging Agents"
    ],
    "source": "https://reference.medscape.com/drug/pylarify-piflufolastat-F-18-4000221",
    "pregnancy": {
        "common": [
            "Not indicated for use in females",
            "There is no information on the risk of adverse developmental outcomes in pregnant females or animals ",
            "All radiopharmaceuticals, including piflufolastat F18, may potentially cause fetal harm depending on fetal stage of development and magnitude of radiation dose"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Not indicated for use in females",
            "There is no information on drug presence in human milk, effects on breastfed infants, or effects on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Monitor for hypersensitivity reactions, particularly in patients with a history of allergy to other drugs and foods; reactions may not be immediate; trained staff and resuscitation equipment should always be available"
            ],
            "specific": [
                {
                    "type": "Risk of image misinterpretation",
                    "description": [
                        "Imaging interpretation errors can occur",
                        "A negative image does not rule out presence of prostate cancer and a positive one does not confirm presence of prostate cancer",
                        "Drug uptake is not specific for prostate cancer and may occur with other types of cancer, nonmalignant processes, and in normal tissues",
                        "Clinical correlation, which may include histopathological evaluation of suspected prostate cancer site, is recommended"
                    ]
                },
                {
                    "type": "Radiation risks ",
                    "description": [
                        "Diagnostic radiopharmaceuticals expose patients to radiation",
                        "Radiation exposure is associated with a dose-dependent increased risk of cancer",
                        "Ensure safe drug handling and patient preparation procedures to protect patients and healthcare providers from unintentional radiation exposure"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Androgen-deprivation therapy (ADT) and other therapies targeting the androgen pathway",
                        "ADT and other therapies targeting the androgen pathway (eg, androgen receptor antagonists) may result in changes in uptake of piflufolastat F18 in prostate cancer",
                        "Effect of these therapies on performance has not been established"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": "2"
        },
        {
            "name": "Dysgeusia",
            "percent": "2"
        },
        {
            "name": "Fatigue",
            "percent": "1"
        },
        {
            "name": "Hypersensitivity",
            "percent": "0.2"
        }
    ]
}